Navigation Links
USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
Date:8/19/2008

WASHINGTON, Aug. 19 /PRNewswire-FirstCall/ -- Syngenta Seeds, Inc. and John Deere Risk Protection, Inc. announced today that the U.S. Department of Agriculture's Federal Crop Insurance Corporation (FCIC) has approved Syngenta Agrisure(R) and other approved biotech corn seed brands for a broadened crop insurance endorsement that provides insurance premium discounts to farmers. This extends the program for discounts of certain federally-reinsured crop insurance policies and simplified terms to growers who use multiple biotech corn suppliers.

John Deere Risk Protection, which insures growers against yield risks, and Syngenta, jointly submitted the insurance proposal to the FCIC earlier this year. The crop insurance premium discount for growers of Agrisure seeds will initially be offered in Iowa, Illinois, Indiana, Minnesota, Nebraska, South Dakota and Wisconsin. Additional program details will be announced this fall.

"The FCIC's approval of Agrisure and other traited corn seeds acknowledges reduced risk for growers," said Steve Ligon, Head, Syngenta Seeds Corn and Soybean Commercial Operations. "We worked with John Deere Risk Protection to create a better opportunity for growers to access crop insurance discounts. A unified endorsement aligns with growers' preferences for choice and the crop insurance industry's need for consistent policies across seed brands."

Mark Raymie, Director of Business Operations, John Deere Risk Protection, a managing general agent, said that approval of additional biotech seeds for a premium discount balances the interests of seed suppliers, insurers, agents, the Risk Management Agency and growers to create fair competition and broad choice. "The approval of this endorsement by the FCIC should spark additional discussions regarding how technology can impact risk reduction regardless of the technology provider," said Raymie. "We look forward to conversations that take into consideration the value of choice for growers, importance of market competition, and implementation considerations faced by the crop insurance industry."

Ron Litterer, President of the National Corn Growers Association, said the FCIC decision is a win for growers and the industry overall. "We applaud the work of Syngenta, John Deere Risk Protection and the FCIC and RMA in extending access to the Risk Management Biotechnology Endorsement to growers across a wider portion of the Corn Belt."

Syngenta is a world-leading agribusiness committed to sustainable agriculture through innovative research and technology. The company is a leader in crop protection, and ranks third in the high-value commercial seeds market. Sales in 2007 were approximately $9.2 billion. Syngenta employs over 21,000 people in more than 90 countries. Syngenta is listed on the Swiss stock exchange (SYNN) and in New York (NYSE: SYT). Further information is available at http://www.syngenta.com.

John Deere Risk Protection, Inc. is a subsidiary of John Deere (Deere & Company-NYSE: DE), the world's leading provider of advanced products and services for agriculture and forestry and a major provider of advanced products and services for construction, lawn and turf care, landscaping and irrigation. John Deere also provides financial services worldwide and manufactures and markets engines used in heavy equipment. Since it was founded in 1837, the company has extended its heritage of integrity, quality, commitment and innovation around the globe.

Agrisure(R) is a registered trademark of a Syngenta Group Company.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.


'/>"/>
SOURCE Syngenta
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, ... a fully 21 CFR Part 11-compliant email client designed to provide product vigilance ...
(Date:1/19/2017)... ... 18, 2017 , ... The American Medical Informatics Association (AMIA) ... Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should ... AMIA recommended that NIH earmark funding for researchers to produce and execute data ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 /PRNewswire/ ... expected to reach USD 92.9 billion by 2025, ... Research, Inc. Pharmaceutical industry has been adaptive of ... functions as early as 2002. Among the services ... the forerunners. For instance, Johnson & Johnson was ...
Breaking Biology Technology:
(Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
(Date:12/7/2016)... to a new market research report "Emotion Detection and Recognition Market by Technology ... End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, the ... USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):